![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 40, 37178-37185, October 5, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Molecular Sciences, Pfizer Global Research
and Development, Ann Arbor, Michigan 48105
Received for publication, April 26, 2001, and in revised form, July 27, 2001
Transcription factor GATA-4 plays critical roles
in controlling heart development and cardiac hypertrophy. To understand
how GATA-4 functions under diverse conditions, we sought to identify its coactivators. We tested p300 as a coactivator in
GATA-4-dependent transient transcription assays in NIH3T3
cells and found that p300 synergistically activated
GATA-4-dependent transcription on both synthetic and
natural promoters. Direct physical interactions between the N- and
C-zinc finger domains of GATA-4 and the cysteine/histidine-rich region
3 (C/H3) of p300 were identified in immunoprecipitation and glutathione
S-transferase pull-down experiments. Deletion of the
C/H3 region of p300 abolished its coactivator activity indicating that
the physical interaction was required for functional synergy. Through
the use of a series of GATA-4 zinc finger mutants, the amino acids WRR
in the C finger were identified as critical to the interaction. The
adenoviral E1A protein or a peptide encoding the C/H3 region of p300
could inhibit GATA-4-dependent transcription, presumably by
competing for p300 binding. Furthermore, deletion of the region of p300
encoding the histone acetyltransferase activity abolished its effect on
GATA-4-dependent transcriptional activity. These results
establish that p300 acts as a GATA-4 coactivator and that the p300
histone acetyltransferase activity is necessary for the functional interaction.
Members of the GATA-4/5/6 subfamily of GATA-binding proteins
participate in heart development (1-4), in the expression of genes in
the adult heart, and in the adaptive response of the heart to
pathological stresses (5-7). Since GATA-4 controls gene expression in
many cellular environments, its activity is likely regulated by
post-translational modifications such as phosphorylation or acetylation
as has been shown for GATA-1 (8-10), or by interacting with other
proteins (11-15).
GATA-4 mRNA is present in the heart at embryonic day 8, is
expressed throughout development and is readily detectable in the adult
mouse heart (12). In GATA-4 knockout mice the precardiac mesoderm fails
to migrate to the ventral midline resulting in the formation of two
aberrant heart tubes. Although cardiac myocytes form in GATA-4 null
mouse embryos the role of GATA-4 in this process remains obscure
because the level of GATA-6 mRNA is up-regulated in mutant embryos.
In P19 embryonal carcinoma cells, inhibition of GATA-4 expression
prevents the development of cardiac muscle cells while ectopic
expression of GATA-4 accelerates cardiogenesis and increases the number
of cardiac myocytes obtained by 10-fold (16). Thus, the possibility
remains that GATA-4 may participate in the cardiogenic process. GATA-4
has been shown to interact with the homeobox protein Nkx 2.5/Csx which
also expressed early in the developing heart (11). This interaction
results in synergistic activation of the atrial natriuretic factor gene
and activates cardiogenesis in P19 cells to a greater degree than
GATA-4 alone (11, 12).
Several observations suggest that GATA-4 activity is involved in
cardiac muscle hypertrophy associated with pressure overload. First,
mutation of GATA-binding sites in the promoters of two hypertrophy
responsive genes, encoding angiotensin receptor type 1a, and A potential GATA-4 co-activator is p300. p300 p300 has been shown to increase the activity of several transcription
factors including cAMP-response element-binding protein, p53,
signal transducers and activators of transcription, HNF4, MyoD, GATA-1,
GATA-5, and GATA-6. p300 possesses an intrinsic histone
acetyltransferase (HAT) activity that can acetylate histones to modify
chromatin structure as well as other transcription factors (24-29). In
addition, p300 has multiple activation domains and interacts directly
with TATA-binding protein and transcription factor IIB (30-32). These
studies demonstrate that p300 can influence transcription through
multiple mechanisms.
In the present study, we investigate the potential interactions between
GATA-4 and p300. p300 was found to synergistically enhance the
transcriptional activity of GATA-4 on an artificial reporter containing
regulatory GATA sites from both the ANF and Plasmid Constructs--
pMT-GATA-4 (2) was obtained from Dr.
David Wilson. CMV-p300HA, pGEM-E1A, and GST-E1A were obtained from Drs.
D. Livingston, T. Leff, and D. Chakravarti, respectively. pFLAG-CMV-2
was from Sigma. Sequences encoding peptide fragments of GATA-4 fused to the GAL4 DNA-binding domain (DBD) (Gal4-GATA-4) were cloned into pM
(CLONTECH). Clones encoding peptide fragments of
GATA-4 fused to glutathione S-transferase (GST-GATA-4) were
generated by subcloning GATA-4 PCR fragments from the appropriate
Gal4-GATA-4 plasmids into the EcoRI and BamHI
sites of pGEX4T-1 (Amersham Pharmacia Biotech). GATA-4 N-zinc
finger-(1-284) and C-zinc finger-(253-441) constructs and mutants
thereof were derived from the full-length GATA-4 wild type and mutants
by PCR and cloned into pRSET (Invitrogen) vector (N-zinc finger)
or pcDNA6-myc/his (C-zinc finger). pFLAG-GATA-4 was made
by subcloning the EcoRI GATA-4 fragment from pMT2GATA-4 into
pFLAG-CMV-2. pFLAG-CMV-2-BAP encoding a FLAG-tagged bacterial alkaline
phosphatase (BAP) was from Sigma. DNA sequences encoding p300 N1 (AAs
1-597), N2 (AAs 598-1185), N3 (AAs 1186-1860), and C (AAs
1861-2414) were generated by PCR and cloned into pRSET. p300 ( Immunoprecipitation and Western Blot Analysis--
COS7 cells
were transfected with plasmids encoding FLAG-tagged GATA-4, HA-p300, or
both. After 72 h, cells were harvested and lysed at 4 °C in
lysis buffer A (1% Triton, 25 mM Tris-HCl, pH 7.4, 1 mM CaCl2) and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml aprotinin). The lysates were incubated
with FLAG-agarose for 2 h at room temperature, and the beads were
washed 4 times with lysis buffer for 1 min at room temperature and
eluted with SDS sample buffer. The samples were subjected to 8%
SDS-PAGE and blotted with rat anti-HA antibody (Roche Molecular
Biochemicals) and detected with ECL chemiluminescence reagents
(Amersham Pharmacia Biotech) according to the manufacturer's protocol.
NIH3T3 cells were transfected with pcDNA-His-GATA-4, Gal-DBD-1-80,
80-214, 214-441, and CMV-p300. The cells were lysed at 4 °C in
lysis buffer B (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.5% Nonidet P-40) containing protease inhibitors (as above). Lysates were clarified by centrifugation at 18,000 × g
for 10 min. The lysate proteins were immunoprecipitated overnight at 4 °C with anti-Gal4-DBD antibody (Santa Cruz Biotechnology) or anti-T7 tag antibody (Novogen), followed by precipitation with 50 µl
of protein A/G-Sepharose for 2 h at 4 °C. After 4 washes with
lysis buffer B (described above), the immunoprecipitates were eluted by
boiling for 5 min in Laemmli sample buffer. The resulting
immunoprecipitates were electrophoresed on 4-20% sodium dodecyl
sulfate-polyacrylamide gradient gels, transferred onto a nitrocellulose
membrane, and immunoblotted with rat anti-HA antibody. The blots were
developed with ECL chemiluminescence reagents.
GST Pull-down Assays--
All GST fusion proteins were expressed
in Escherichia coli BL21 cells. The bacterial cultures were
induced by 1 mM
isopropyl-D-thiogalactopyranoside for 4 h. The
bacteria were then lysed by sonication in phosphate-buffered saline
containing protease inhibitors (as above). The bacterial lysates were
brought to 1% Triton and incubated for 1 h at 4 °C followed by
centrifugation at 20,000 × g for 15 min. The pellet was discarded and soluble extracts were incubated with
glutathione-Sepharose beads (Amersham Pharmacia Biotech) for 2 h
at 4 °C before washing three times by inversion for 1 min at room
temperature in phosphate-buffered saline containing protease inhibitors
lysis buffer. The concentration of proteins immobilized on beads was
quantified by SDS-PAGE and titrated against bovine serum albumin
standards (Sigma) after Coomassie Blue staining. Binding assays were
performed with radioactively labeled proteins synthesized in
vitro using a TNT-coupled reticulocyte lysate system (Promega) in
the presence of 35S-labeled methionine (Amersham Pharmacia
Biotech). Equal amounts of immobilized GST fusion proteins were
incubated for 2 h at 4 °C with 10 µl of
35S-labeled proteins in GST binding buffer (40 mM Hepes, pH 7.2, 50 mM Na acetate, pH 7.0, 200 mM NaCl, 2 mM EDTA, 5 mM
dithiothreitol, 0.5% Nonidet P-40, protease inhibitors, and 2 mg of
bovine serum albumin per ml). After four 1-min washes at room
temperature in GST binding buffer, beads were boiled in SDS sample
buffer, resolved by SDS-PAGE, and analyzed by autoradiography.
Transient Transfection Assay--
NIH3T3 cells were maintained
in Dulbecco's modified Eagle's medium supplemented with 10% fetal
calf serum, 2 mM glutamine, streptomycin (10 g/liter), and
penicillin (10 g/liter). All transfections were performed in 6-well
plates with LipofectAMINE Plus reagents from Life Technologies, Inc.
Cells were transfected with 0.3 µg of luciferase reporter constructs
PREDluc, GATA-4 Transcriptional Activity Is Enhanced by p300--
It has
been suggested that p300 can increase GATA-4 activity in reporter
assays (34). To further characterize this functional interaction, we
examined the ability of p300 to influence GATA-4 transcriptional
activity in transient transfection assays in NIH 3T3 cells. We first
investigated the activity of p300 and GATA-4 on a functional GATA site
from the ANF promoter. This GATA site, located at position
We examined a second hypertrophy responsive promoter for activation by
GATA-4 and p300. On the
Finally we were interested in determining whether or not p300 would
activate GATA-4 on a GATA site from a promoter that is not responsive
to hypertrophic stimuli. To this end we made a reporter plasmid,
containing six GATA sites from the GATA-4 Transcriptional Activity Is Inhibited by E1A--
The
adenovirus E1A protein interacts with p300 and this interaction has
been shown to inhibit the HAT activity of p300 (36, 37). To confirm
that p300 acts as a coactivator of GATA-4, a clone encoding the E1A
protein was co-transfected in selected assays with GATA-4 and p300
(Fig. 2). When E1A was present in these
co-transfection assays, GATA-4/p300-dependent
transcriptional activity was dramatically decreased (Fig. 2).
Interestingly, E1A also inhibited the activity of GATA-4 alone
indicating that endogenous p300 may play a role in the activation of
GATA-4. To demonstrate that the decrease in GATA-4/p300 activity
resulted from an interaction between p300 and E1A, we used a mutant of
E1A (E1A( GATA-4 and p300 Physically Interact--
The functional synergy
observed when these proteins were co-transfected into cells suggested
that they physically interact. In order to determine if such an
interaction could occur in vivo, we examined whether GATA-4
can form complexes with p300 in COS-7 cells. Lysates from cells
transfected with FLAG-tagged GATA-4 and HA-tagged p300 were
immunoprecipitated with the anti-FLAG antibody (Fig.
3A). The co-immunoprecipitated
proteins were analyzed by immunoblotting with the anti-HA antibody.
HA-tagged p300 co-precipitated with GATA-4 in cells transfected with
GATA-4 and p300 (Fig. 3A), but not in cells transfected with
either GATA-4 or p300 alone. These results indicate that GATA-4 and
p300 interact in vivo. To more precisely determine the
region of GATA-4 that interacts with p300, NIH3T3 cells were
co-transfected with plasmids encoding GATA-4 peptides fused to the
Gal4-DNA-binding domain and HA-tagged p300. Complexes were
immunoprecipitated with anti-Gal-DBD antibody and Western blotted with
anti-HA antibody (Fig. 3B). The result showed that GATA-4
AAs 1-80 and 80-214 were unable to precipitate p300 whereas AAs
214-441 bound p300. These results suggested that AAs 214-441 of
GATA-4 contain the interaction domain for p300.
Mapping of the GATA-4 and p300 Domains Required for
Interaction--
In order to define the interacting domains of each
protein, we prepared GST fusion proteins containing various peptides of GATA-4 and determined the ability of each of these to interact with
peptides containing roughly equal portions of p300. GST-GATA-4 fusion
proteins (shown schematically in Fig.
4A) were expressed, purified,
and coupled to glutathione-Sepharose beads. p300 N1 (AA 1-597), N2 (AA
598-1185), N3 (AA 1186-1860), and C (1861-2414) were in
vitro translated in the presence of [35S]methionine.
The in vitro translated fragments were run on a gel and
compared to ensure equal input of protein (data not shown). Equal
amounts of labeled p300 peptides were incubated with GST, GST-GATA-4,
or GST-E1A coupled to glutathione-Sepharose beads. After pelleting and
washing the beads, the protein remaining was separated by
electrophoresis and visualized by autoradiography. The results are
shown in Fig. 4, B and C. GATA-4 peptides 1-80, 80-214, and 294-441 did not significantly pull down any fragment of
p300. These sequences encompass all of the GATA-4 protein except the
zinc fingers. Peptides of GATA-4 containing the N-finger-(80-250) and
C-finger-(241-378) interacted significantly with only the N3 fragment
of p300. These results indicate that the N- and C-fingers of GATA-4 can
interact with the N3 peptide of p300 independently. N3 contains AAs
1185-1860 that includes the cysteine/histidine-rich 3 (C/H3) region of
p300. To further define sequences within the N3 region of p300 that
interact with GATA-4, we generated in vitro translated
peptides containing AAs 1200-1513, 1200-1587, and 1200-1817 of p300.
After analysis to confirm equal input of protein, these peptides were
used in GST pull-down assays with peptides of GATA-4 containing the N-
and C-zinc fingers (Fig. 4D). p300 peptides containing AAs
from 1200 to 1587 showed weak interactions with GATA-4, however, the
interaction was greatly enhanced when the peptide included additional
AAs from 1588 to 1817. Of the input p300 (1200-1817), ~25%
interacted with GATA-4 (Fig. 4D). These results suggest that
AA 1587-1817 is the region that interacts with each zinc finger domain
of GATA-4 with high affinity. This corresponds to the C/H3 region of
p300. The C/H3 region is known to interact with the adenovirus E1A
protein (36). It is noteworthy that GATA-4 and E1A interact with the
same region of p300 since we show above that E1A can block the
GATA-4/p300 synergistic transcriptional activation. Our results suggest
that the transcriptional inhibition might be due to direct competition
between E1A and GATA-4 for binding to the C/H3 region of p300.
Zinc Finger Amino Acids Involved in Interaction with
p300--
Having identified the region of p300 that interacts with
GATA-4, we wanted to determine the AAs in the zinc fingers of GATA-4 that are important for p300 interaction. We used zinc finger mutants of
GATA-4 available in our
laboratory2 to produce N- and
C-finger mutations in plasmids encoding AAs 80-250 and 253-441 of
GATA-4, respectively (Fig.
5A). The wild type and mutant
GATA-4 peptides were synthesized in TNT reactions in the presence of
[35S]methionine and used in pull-down experiments with
GST-p300-(1587-1817) immobilized on glutathione-Sepharose beads.
Deletion of the N-finger (Fig. 5C, Ndel) caused a
marked reduction in the ability of the peptide to interact with p300.
Surprisingly, none of the N-finger substitution mutations had any
significant effect on p300 binding. Each of the mutant peptides bound
as well as the wild type protein (Fig. 5C). This suggests
that the amino acid substitutions used in this experiment did not
disrupt contacts with p300 sufficiently to prevent binding. Either
larger areas of substitution or different amino acid substitutions may
be necessary to reveal the critical area for interaction. Similarly, as
compared with the wild type C-finger peptide, most C-finger mutants
retained the ability to bind to p300 (Fig. 5B). However, the
one notable exception was the WRR to SSS substitution of the C-finger
that abolished the interaction with p300 (Fig. 5B, lane 3).
The C-finger deletion also diminished binding. This result demonstrates
that the WRR residues in the C-finger are critical for p300 binding. It
should be noted that the C-finger WRR mutant is transcriptionally
inactive but this effect cannot be directly attributed to a loss of the ability to interact with p300 since this mutant also does not bind DNA
(11).
Deletion of the C/H3 Domain, but Not the C/H1 Domain, of p300
Inhibits GATA-4 Transcriptional Activity--
Since the C/H3 region is
required for interaction with GATA-4, we expected that deletion of this
region from p300 would result in decreased transcriptional activation.
Furthermore, since other regions of p300 are known to interact with
several other proteins, including coactivators, we were interested to
determine if a C/H3 deletion mutant of p300 might act as a negative
regulator by sequestering other potential cofactors of GATA-4. If so,
the activity of GATA-4 alone would be expected to be lower in the
presence of the C/H3 deletion mutant. To address these issues, a p300
clone was constructed that lacked the coding sequence for a portion of
the C/H3 region (AAs 1737 to 1836) (p300 The C/H3 Domain of p300 Can Inhibit GATA-4 Transcription--
Our
results establish that AAs 1587-1817, containing the C/H3 region of
p300, are required for the physical interaction with GATA-4 (Fig.
4D). Furthermore, deletion of the C/H3 region of p300
inhibits GATA-4-dependent transcription (Fig. 6) suggesting that binding of GATA-4 by p300 is required for activity. If the C/H3
interaction is required for the functional synergy between GATA-4 and
p300 then overexpression of a peptide containing only the C/H3 region
should be able to compete with exogenous and endogenous p300 for GATA-4
binding and thereby attenuate GATA-4 dependent transcriptional
activity. To test this, a PCR product encoding the C/H3 region was
cloned into an expression vector in-frame with 3 nuclear localization
signals. This clone was co-transfected with the ANF promoter reporter
and expression vectors encoding GATA-4, p300, or both (Fig.
7). As shown in previous experiments, p300 increased the activity of GATA-4 on this promoter. However, when
the plasmids encoding the C/H3 peptide and p300 were co-transfected the
transcriptional activity was severely attenuated (from 8- to 3-fold).
This inhibition was also seen in the absence of added p300, consistent
with the E1A experiment (Fig. 2). These results establish that the C/H3
region of p300 can inhibit GATA-4 transcription presumably by binding
to GATA-4 and preventing its interaction with wild type p300. They also
lend further support to the hypothesis that p300 is required for GATA-4
transcription.
The HAT Domain of p300 Is Required for Activation of GATA-4
Transcriptional Activity--
p300 has been shown to act alone and in
complexes with other proteins to influence transcription. The intrinsic
HAT activity of p300 can act directly to modify chromatin structure
(38), however, p300 may also recruit other histone acetyltransferases to the transcriptional complex (39). To determine whether the intrinsic
HAT activity of p300 is required for GATA-4 function, we generated a
mutant that encodes a p300 protein deleted for 20 amino acids (AA
1415-1434) in the HAT domain (40). This mutant or wild type p300 were
co-transfected with an HA-tagged GATA-4 expression vector in NIH3T3
cells transient transfection experiments (Fig.
8). It can be seen that with increasing
amounts of wild type p300, HA-tagged GATA-4 was activated albeit to
levels that was lower than native GATA-4. In contrast, increasing
amounts of the p300 HAT mutant did not increase transcriptional
activity of GATA-4. Protein extracts made from parallel plates in this experiment were used in immunoprecipitation experiments using anti-HA
antibody. The precipitates were run on SDS gels and Western blot
analysis was performed with antibodies against acetylated lysine. These
experiments failed to detect any acetylation of GATA-4 in any sample
even though a similar experiment with GATA-1 could detect acetylation
(data not shown). These results indicate that the HAT domain of p300 is
required for GATA-4 activation and support the interpretation that this
acetyltransferase activity is not directed at GATA-4.
In this study we used multiple approaches to demonstrate both
physical and functional interactions between GATA-4 and p300. Our
results confirm a previous comment that GATA-4 might interact with CBP
(34). They are also consistent with a recent study indicating that p300
can coactivate GATA-5 on the ANF promoter (23, 42). We extend these
previous observations by: 1) demonstrating functional synergy between
GATA-4 and p300 on artificial and natural cardiac promoters; 2)
defining the regions of GATA-4 and p300 that are required for the
physical interaction; 3) demonstrating that the mutation of amino acids
WRR to SSS in the C-finger of GATA-4 prevent p300 binding to that
finger; 4) demonstrating that a deletion mutant of p300 that lacks the
GATA-4 interaction domain (C/H3) inhibits GATA-4-dependent
transcription; 5) demonstrating that overexpression of the p300 C/H3
domain can inhibit GATA-4-dependent transcription; and 6)
demonstrating that the HAT domain of p300 is required for p300
coactivation of GATA-4 transcription. It is noteworthy that p300
appears to act as a GATA-4 coactivator on GATA sites from the ANF,
The observation that the p300 C/H3 domain is required for interaction
with the zinc fingers of GATA-4 was established in a series of GST
pull-down experiments (Fig. 4). As a positive control we confirmed that
E1A interacts with the same region (43). The C/H3 domain also interacts
with several other regulatory proteins including MyoD (44, 45), PCAF
(43), RNA helicase and RNA polymerase II (46), pp90RSK
(47), C/EBP The localization of the GATA-4-binding site in p300, reinforces the
functional data and confirms an important role for p300 in GATA-4
transcriptional activation. E1A blocks GATA-4 transcriptional activation most likely by competing with it for binding to the p300
C/H3 domain. To confirm this interpretation, we used a C/H3 deletion
mutant that has been shown to inhibit the activity of transcription
factors known to interact with p300 through this site (49). The C/H3
deletion blocked GATA-4-dependent transcription (Fig. 6),
indicating that p300 is essential for GATA-4 function. Furthermore,
when the C/H3 domain was expressed in the presence of GATA-4 and p300
or GATA-4 alone, transcriptional activity was repressed (Fig. 7).
Similar to the E1A protein, the C/H3 domain peptide presumably competes
with co-transfected and endogenous p300 for GATA-4 binding. Taken
together, our results establish that GATA-4 activity is dependent, in
part, on a functional and physical interaction with the coactivator
p300. The work presented here does not address the mechanism of this
synergistic interaction.
p300 interacts with the zinc fingers of GATA-4 (Fig. 4). It joins the
list of several other regulatory factors that interact with the zinc
fingers of GATA-4 including Nkx 2.5 (11, 12, 15), NF-AT 3 (7), MEF-2
(17), GATA-6 (35), and serum response factor (13, 14) that interact
with the C-finger and FOG-2 that interacts with the N finger (50, 51).
p300 is unique in that it can bind to each finger individually. The
ability of p300 to bind either zinc finger might prevent potential
interference with the activity of additional transcription factors that
might jointly interact with individual fingers.
Transcription of a class II gene by RNA polymerase II requires the
assembly of general transcription factors and coactivators around the
transcription start site in the promoter. When tethered to DNA,
eukaryotic transcriptional activation domains can recruit the general
transcription machinery in order to stimulate gene transcription (52).
The general transcription machinery includes RNA polymerase II, the
general transcription factors, and cofactors known as adaptors or
coactivators (53). In many cases, p300 interacts with activation
domains to influence function as is the case with VP16 and SP1 (38) and
the sterol response element-binding protein (54). Although GATA-4
contains two activation domains (AA 1-74 and 130-177) (55), p300 did
not directly interact with these regions of GATA-4. Furthermore, p300
did not enhance transcriptional activity of a mutant GATA-4( Acetylation of the N-terminal portion of histones is one mechanism by
which p300 stimulates transcription. p300 and its interacting protein
P/CAF both possess intrinsic acetyltransferase activity, and this
activity is involved in stimulating gene transcription (38, 56). Both
P/CAF (43) and GATA-4 interact with the C/H3 domain of p300. Depending
upon the nature of this binding, these factors may compete or cooperate
for binding to p300. p300 can also activate transcription by a
HAT-independent mechanism (32, 39, 57). Here we show that the p300 HAT
activity is required for coactivation of GATA-4 transcription activity
(Fig. 8). The HAT mutant was capable of binding to GATA-4,3
indicating that its inability to coactivate GATA-4 is not due to
deletion of an interacting domain. Taken together, our results indicate
that the recruitment of acetyltransferase activity of p300 by the zinc
finger domains of GATA-4 is necessary for GATA-4-dependent transcription.
GATA-1 has been shown to be acetylated by p300 and mutations in either
of the two acetylation sites impaired the ability of GATA-1 to trigger
erythroid differentiation without affecting its DNA binding activity
(10). These lysine-rich motifs are located to the C terminus of each
the zinc finger and are conserved among the members of GATA 1/2/3
family (58). These sites are not conserved in the GATA 4/5/6 family
suggesting a different regulatory mechanism. We did not detect
acetylation of GATA-4 by p300 in cultured cells by immunoprecipitation
and Western blot analysis with anti-acetyllysine antibodies.
Furthermore, synthetic peptides containing potential acetylation sites
of GATA-4 were not significantly acetylated by p300 in vitro
compared with GATA-1 peptide and histone.3 These results
suggest that direct acetylation of GATA-4 by p300 is an unlikely
regulatory mechanism but do not rule out the possibility that GATA-4 is
acetylated at other sites.
The results presented here suggest that the activity of GATA-4 is
dependent, in part, on its physical interaction and functional cooperation with the coactivator protein p300. This activity may be
important at all stages of heart development as well as in the
hypertrophic response to stresses on the heart since GATA-4 has been
shown to function in these processes. However, we do not believe that
p300 modulates GATA protein-dependent promoter selectivity.
GATA-4 and -6 are highly homologous in the zinc finger regions; 3 AA
different in the N-finger and 1 AA different in the C-finger. While we
did not directly test whether p300 synergizes with GATA-6 on the ANF
promoter, this possibility seems likely because p300 and GATA-6 are
known to interact (41). This is in contrast to the observation that
NKX2.5 interacts with the C-finger of GATA-4 but not GATA-6 (12). Since
p300 can have multiple interactions and functions, it is not possible
to ascribe any specific role to the GATA-4·p300 complex in cardiac
development or hypertrophy. However, the heart defects seen in the
p300 We thank Drs. David Livingston, Todd Leff,
David Wilson, and D. Chakravarti for providing plasmids, Dr. Bing Ren
for original construction of several GATA-4 zinc finger
mutants, Dr. Roland Kwok for helpful discussion on the GATA-4
acetylation experiment, and Drs. Todd Leff and Jeff Molkentin for
critical reading of the manuscript. We also thank Jonathan Dascenzo for
reformatting the figures for publication.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
To whom correspondence should be addressed: Dept. of Molecular
Sciences, Pfizer Global Research and Development, 2800 Plymouth Rd.,
Ann Arbor, MI 48105. Tel.: 734-622-2700; Fax: 734-622-5668; E-mail:
bruce.markham@pfizer.com.
Published, JBC Papers in Press, July 31, 2001, DOI 10.1074/jbc.M103731200
2
B. Ren and B. E. Markham, unpublished results.
3
Y.-S. Dai and B. E. Markham, unpublished results.
The abbreviations used are:
MHC, myosin heavy
chain;
AAs, amino acids;
ANF, atrial natriuretic factor;
BAP, bacterial
alkaline phosphatase;
C-finger, carboxyl-terminal zinc finger;
C/H1, cystine/histidine-rich region 1;
C/H3, cystine/histidine-rich region 3;
E1A, adenoviral 12S E1A protein;
GST, glutathione
S-transferase;
HAT, histone acetyltransferase;
N-finger, amino-terminal zinc finger;
PCR, polymerase chain reaction;
DBD, DNA-binding protein;
PAGE, polyacrylamide gel electrophoresis;
HA, hemagglutinin.
p300 Functions as a Coactivator of Transcription Factor
GATA-4*
and
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-myosin
heavy chain (MHC),1 diminish
or ablate the pressure overload response (5, 6, 18). Second, GATA-4 was
detected in nuclear extracts from pressure overloaded hearts but not
normal hearts by gel shift experiments (5). Third, GATA-4 was shown to
interact with NF-AT3 and overexpression of the calcineurin/NF-AT
pathway was shown to initiate cardiac hypertrophy (7). Fourth, GATA-4
regulates the expression of a number of hypertrophy responsive genes
including those encoding ANF and brain natriuretic peptide (19). These
results suggest that GATA-4, either by itself or in concert with other
regulatory factors, is a regulator of the hypertrophic response.
/
knockout
mice die between 9 and 11.5 days of gestation from heart defects (20). Mutant embryos have enlarged heart cavities, significantly reduced trabeculation, and pericardial effusion. Interestingly, the expression level of the
-MHC gene (the major contractile protein in the fetal
heart) is reduced. This gene is also regulated by GATA-4 (6). The
adenovirus E1A protein, is known to interact with and inhibit the
function of p300 and several other regulatory proteins. When
overexpressed in cardiac myocytes, E1A has been shown to down-regulate
many muscle-specific genes (21, 22). GATA proteins regulate a subset of
these genes. These observations suggest a possible interaction between
GATA proteins and p300. Furthermore, while this work was in
preparation, it was reported that p300 and GATA-5 interact to regulate
the ANF gene (23); however, the mechanism by which p300 coactivates
GATA-5 was not determined.
-MHC promoters in
transient reporter assays. We mapped the regions in GATA-4 and p300
required for their interaction and demonstrate that mutations, which
prevented the interaction, abolished the functional cooperation.
Additionally, co-expression of either a peptide encoding the C/H3
domain of p300 or the adenoviral E1A protein with GATA-4 alone or in
combination with p300 blocks GATA-4-dependent transcriptional activity. Finally, we show that the p300 HAT domain is
required for coactivation of GATA-4 transcription.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
C/H1)
deleting sequences encoding of AAs 348 to 412 and p300 (
C/H3)
encoding a full-length p300 except for a deletion of sequences encoding
AAs 1737 to 1836 were purchased from Upstate Biotechnology. To
construct the p300 HAT deletion mutant, p300 was cloned into
pcDNA3.1 (NotI/HindIII fragment) and the 5'
end of p300 was excised on an XbaI fragment. The vector
containing the 3' sequence was religated and used for PCR-based
mutagenesis (Stratagene). Sequences encoding AAs 1415-1436 of p300
were deleted. The 5' XbaI fragment was then cloned back to
the mutated 3' end via the XbaI site. pCI-E1A was produced
by subcloning E1A from pGEM-E1A into the pCI vector (Promega).
E1A(
2-36) was constructed by deleting AAs 2-36 of E1A. The
reporter plasmid pTATAluc was made by cloning an oligo containing the
rat
-myosin heavy chain TATA sequence into the HindIII
site of pGL2 basic (Promega). The sequence of the plus strand of the
TATA oligo was 5'-AGCTTCGTGCAGTATAAAGGG-3'. pANFGATA6luc contains 6 GATA sites from the ANF promoter (at position
120) cloned into the
KpnI site of pTATAluc. The sequence of the plus strand of
the ANF GATA oligonucleotide is 5'-CTGATACTCTGATAACTCTGATAACTGGTAC-3'. The native ANF reporter plasmid (
638/Luc) was from Youngsook Lee
(11). The reporter containing the
-MHC GATA sites has 3 copies of
the oligonucleotide PRED (33) cloned into the SmaI site of
pTATAluc. The
-MHC promoter was a gift from K. Ojama. The fragment
containing the
-MHC promoter from the transcription start site to
approximately
2200 was subcloned into pGL2 basic. The sequence of all
clones was verified by DNA sequence analysis.
-MHCluc, ANFluc, or G4-ANFluc, and 0.1 µg of pMT2-GATA-4
or pMT2-CAT, 0.6 µg of pcDNA3-p300 or pcDNA3-p300HAT mutant,
0.6 µg of E1A wild type or E1A Mutant(
2-36). CMV-
-gal (20 ng
in each well) was used as internal control. Luciferase activity was
measured in a microplate luminometer (LB96V; Berthold), normalized to
-Gal activity. Fold activation represents a comparison of the ratio
of luciferase/
-Gal activity for each condition with that of the
reporter vector control which was arbitrarily set at 1. Each value
presented is the average of triplicate samples and is representative of
multiple independent experiments (n greater than or equal to
3). The data were statistically analyzed with Student's t test.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
120 in the
ANF promoter, was recently shown to support both GATA-4 and
GATA-6-dependent transcription (35). From a reporter
containing 6 copies of this GATA site upstream of a TATA sequence,
GATA-4 alone increased activity 15-fold while p300 alone increased
activity about 7.5-fold (Fig.
1A). Together they increased
activity 70-fold over the basal promoter alone, a level that was much
more than additive, indicating a functional synergy between these two
regulatory proteins. This functional synergy was also observed when a
reporter driven by the proximal ANF promoter (
637 to +10) was used
(Fig. 1B). With this natural promoter, GATA-4 alone gave
5-fold activation while p300 alone gave a 40-fold activation,
presumably due to coactivation of other proteins that regulate this
promoter. In combination GATA-4 and p300 activated the ANF promoter
95-fold over basal, a much greater than additive effect. These results
confirm that a functional interaction can occur between GATA-4 and p300
in the context of a natural promoter.

View larger version (17K):
[in a new window]
Fig. 1.
p300 coactivates GATA-4 transcription on
natural and artificial cardiac promoters. NIH3T3 cells were
transfected with indicated reporters (0.3 µg), pMT2-GATA-4 (0.1 µg)
(G4), and CMV-p300 (0.6 µg) (p300), 20 ng of CMV-
-galactosidase
gene in 6-well plates. The cells were harvested after 24 h, and
luciferase and
-gal activities were measured as described under
"Experimental Procedures." A, pTATAluc containing six
copies of GATA-binding sites from ANF promoter (6G4-ANF). B,
the proximal ANF promoter (
637 to +10) luciferase reporter (ANF).
C, pTATAluc containing 6 GATA sites derived from the
-myosin heavy chain promoter (PRED). D, the
-myosin
heavy chain promoter luciferase reporter (
-MHC).
-MHC promoter GATA-4 or p300 alone activated
reporter activity 4-fold (Fig. 1D). In combination GATA-4
and p300 gave a 12-fold activation that was more than additive but less
than multiplicative. These results indicate that p300 and GATA-4
functionally cooperate to activate transcription in a natural promoter context.
-MHC promoter upstream of a TATA
sequence, which was co-transfected with the GATA-4 expression vector
with or without p300 expression (Fig. 1C). In this assay
GATA-4 alone increased expression from the artificial promoter nearly
9-fold while p300 alone increased 3-fold. The combination of GATA-4 and
p300 increased expression 115-fold over the control (luciferase
reporter alone), which represents a 12-fold increase over GATA-4 alone.
In addition, p300 did not measurably influence the amount of GATA-4
produced from the expression vector as determined by Western blotting
(data not shown). Thus, p300 appears to supplement GATA-4 activity on
sites from both hypertrophy responsive and non-responsive genes. These
results also indicate that GATA-4 and p300 can functionally cooperate to increase GATA-4-dependent transcription from GATA sites
in both artificial and natural promoter contexts.
2-36) from which AAs 2 to 36 were deleted. This E1A mutant
is deficient in binding to p300 (36). As shown in Fig. 2, E1A(
2-36)
was much less effective than wild type E1A in inhibiting the
GATA-4/p300 functional cooperation. These results demonstrate that E1A
can inhibit GATA-4/p300-dependent activity presumably by
sequestration of p300. These results provide further evidence that
GATA-4 and p300 can functionally cooperate to increase activity from
GATA-dependent promoters.

View larger version (17K):
[in a new window]
Fig. 2.
Effect of E1A and
E1A(
2-36) on GATA-4 transcription. NIH
3T3 cells were transiently transfected with 0.3 µg of 6G4-ANF
together with expression vector pMT2-GATA-4 (0.1 µg) (G4), CMV-p300
(0.6 µg) (p300), E1A wild type (0.6 µg) (E1AWT), or E1A mutant
(
2-36) (0.6 µg) (E1AMUT), as indicated, and 20 ng of
CMV-
-galactosidase. Assays were performed and analyzed as described
under "Experimental Procedures."

View larger version (20K):
[in a new window]
Fig. 3.
GATA-4 and p300 interact in
vivo. A, cell lysates were prepared from
COS-7 cells transfected with HA-p300 or HA-p300 and Flag-GATA-4 as
described under "Experimental Procedures." The cell lysates were
incubated with FLAG-agarose and protein was eluted from the washed
beads and subjected to 8% SDS-PAGE. Precipitated p300HA was detected
using anti-HA antibody (B). NIH3T3 cells were transfected
with Gal4DBD or clones encoding GATA-4 peptides AAs 1-80, 80-214, and
214-441 fused to Gal4-DBD as indicated and HA-tagged p300. The cell
lysates were prepared from the transfected cells and incubated with
mouse anti-Gal4-DBD antibody and precipitated with protein
A/G-agarose. The immunoprecipitates were subjected to
SDS-PAGE. Precipitated p300HA was detected using anti-HA
antibody.

View larger version (23K):
[in a new window]
Fig. 4.
N- and C-zinc finger domains of GATA-4
interact with C/H3 region of p300. Radioactively labeled peptides
of p300 produced by in vitro translation were incubated with
GST fusion proteins encoding portions of GATA-4 as indicated. GST
pull-down experiments were performed as described under "Experimental
Procedures." A, schematic representation GATA-4 and p300
peptides used to localize the interaction domains and summary of
results. B, GST-GATA-4 fusion proteins, as indicated, were
incubated with 35S-labeled p300 AAs 598-1185 (N2) or AAs
1186-1860 (N3). GST-E1A was used as a positive control for binding to
p300 N3 region. C, GST-GATA-4 fusion proteins, as indicated,
were incubated with 35S-labeled p300 AAs 1-597 (N1) or AAs
1861-2414 (C). D, GST-GATA-4 fusion proteins
(AAs 80-250 or 241-378) were incubated with 35S-labeled
p300 peptides containing AAs 1200-1513, 1200-1587, or 1200-1817 as
indicated. In B-D, the figure shows an autoradiogram of the
p300 peptide, as indicated, that interacted with the GST-GATA-4 peptide
indicated at the top of the figure.

View larger version (19K):
[in a new window]
Fig. 5.
Identification of the amino acid residues in
the C-finger of GATA-4 that are critical for interacting with
p300. Radioactively labeled wild type or mutant peptides of GATA-4
including AAs 80-250 (N-finger) or AAs 253-441, produced by in
vitro translation, were incubated with a GST fusion protein
encoding the N3 region of p300. GST pull-down experiments were
performed as described under "Experimental Procedures."
A, a schematic representation of the amino acid substitution
mutants of the N- and C-fingers of GATA-4 used to map the p300
interaction region. B, 35S-labeled C-finger wild
type and mutant peptides, as indicated, were incubated with GST-N3.
C, 35S-labeled N-finger wild type and mutant
peptides, as indicated, were incubated with GST-N3. In B and
C the figure shows an autoradiogram of the GATA-4 peptide,
as indicated, that interacted with the GST-N3.
1737-1836). As a control,
we also prepared a clone encoding a p300 protein lacking amino acids
from the C/H1 region (p300
348-412) that is not involved in the
interaction with GATA-4. GATA-4 was expressed in cells in combination
with wild type or C/H3 or C/H1 deleted p300 and assayed for activity from an artificial promoter-reporter containing multiple
-myosin heavy chain GATA sites (PRED, Fig. 6). As
shown previously, p300 synergistically activated GATA-4 activity. The
C/H1 deleted p300 also increased GATA-4 activity albeit not as much as
the wild type protein. In contrast, the C/H3 deleted p300 inhibited
GATA-4 activity compared with GATA-4 alone. These results demonstrate that the C/H3 region of p300 is required for synergistic activation of
GATA-4 and that the presence of this mutant protein has a negative effect on GATA-4 activity. The latter result is indicative of the
response predicted if the C/H3 deletion mutant was titrating out other
GATA-4 coactivator proteins.

View larger version (15K):
[in a new window]
Fig. 6.
p300
C/H3 blocks
GATA-4 transcription. NIH 3T3 cells were transfected with 0.3 µg
of the PRED reporter (as described in the legend to Fig. 1) alone or
with pMT2-GATA-4 (0.1 µg), p300 (0.6 µg) (p300 WT), p300
C/H3
(0.6 µg) (p300C/H3del), and p300
CH1 (0.6 µg) (p300C/H1del), as
indicated, and 20 ng of CMV-
-galactosidase. Transient transfection
experiments were performed and analyzed as described under
"Experimental Procedures."

View larger version (13K):
[in a new window]
Fig. 7.
The C/H3 region of p300 blocks GATA-4
transcription. NIH 3T3 cells were transfected with the ANFluc
reporter (0.3 µg), alone or in combination with pMT2-GATA-4 (0.1 µg), p300 (0.6 µg), p300C/H3 (0.6 µg) (CH3), as indicated, and
CMV-
-galactosidase (20 ng). Transient transfection experiments were
performed and analyzed as described under "Experimental
Procedures."

View larger version (15K):
[in a new window]
Fig. 8.
The acetyltransferase activity of p300 is
required for coactivation of GATA-4 transcription. NIH 3T3 cells
were transfected with 0.3 µg of the PRED reporter alone
(PRED) or in combination with CMV-Flag-GATA-4 (0.1 µg)
(
), and increasing amounts of pCMV-p300 (0 to 0.8 µg), or
pCMV-p300 HAT mutant (0 to 0.8 µg) as indicated. pCMV-Flag-BAP (0.1 µg) was added with PRED as a control for CMV-Flag-GATA-4. Transient
transfection experiments were analyzed as described under
"Experimental Procedures." Wild type p300 activity is represented
by the closed circles and p300 HAT mutant activity by the
closed triangles.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-MHC, and
-MHC promoters. This lack of differential activity
suggests that the p300·GATA-4 complex is required for appropriate
GATA-4 regulatory processes in most promoter contexts.
(48), and GATA-1 (34). Our results are similar to those
previously reported for GATA-1 that established that its zinc finger
domain interacts with C/H3 domain.
2-213)
lacking these activation domains even though it could physically
interact with the mutant.3
This suggests that p300 plays a role beyond that of histone acetylation in stimulating GATA-4-dependent transcription. One possible
role for p300 is to help recruit or stabilize the interaction of other transcriptional regulatory factors with the activation domains. It is
also possible that p300 competes with a corepressor, such as FOG 2, for
GATA-4 binding.
/
mouse (20), the observation that the E1A protein
can repress cardiac gene transcription (21, 22, 59), and the
observation that the C/H3 domain of p300 can be phosphorylated by
protein kinase B (60) that is active in the hypertrophic heart (61) suggest that this is an important area for future study.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Present address: Childrens Hospital Medical Center, Division of
Molecular Cardiology and Biology, 3333 Burnet Ave., Cincinnati, OH
45229-3039.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Molkentin, J. D.,
and Olson, E. N.
(1997)
Circulation
96,
3833-3835
2.
Arceci, R. J.,
King, A. A.,
Simon, M. C.,
Orkin, S. H.,
and Wilson, D. B.
(1993)
Mol. Cell. Biol.
13,
2235-2246
3.
Grepin, C.,
Robitaille, L.,
Antakly, T.,
and Nemer, M.
(1995)
Mol. Cell. Biol.
15,
4095-4102
4.
Kuo, C. T.,
Morrisey, E. E.,
Anandappa, R.,
Sigrist, K.,
Lu, M. M.,
Parmacek, M. S.,
Soudais, C.,
and Leiden, J. M.
(1997)
Genes Dev.
11,
1048-1060
5.
Herzig, T. C.,
Jobe, S. M.,
Aoki, H.,
Molkentin, J. D.,
Cowley, A. W., Jr.,
Izumo, S.,
and Markham, B. E.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7543-7548
6.
Hasegawa, K.,
Lee, S. J.,
Jobe, S. M.,
Markham, B. E.,
and Kitsis, R. N.
(1997)
Circulation
96,
3943-3953
7.
Molkentin, J. D.,
Lu, J. R.,
Antos, C. L.,
Markham, B.,
Richardson, J.,
Robbins, J.,
Grant, S. R.,
and Olson, E. N.
(1998)
Cell
93,
215-228
8.
Crossley, M.,
and Orkin, S. H.
(1994)
J. Biol. Chem.
269,
16589-16596
9.
Partington, G. A.,
and Patient, R. K.
(1999)
Nucleic Acids Res.
27,
1168-1175
10.
Hung, H. L.,
Lau, J.,
Kim, A. Y.,
Weiss, M. J.,
and Blobel, G. A.
(1999)
Mol. Cell. Biol.
19,
3496-3505
11.
Lee, Y.,
Shioi, T.,
Kasahara, H.,
Jobe, S. M.,
Wiese, R. J.,
Markham, B. E.,
and Izumo, S.
(1998)
Mol. Cell. Biol.
18,
3120-3129
12.
Durocher, D.,
Charron, F.,
Warren, R.,
Schwartz, R. J.,
and Nemer, M.
(1997)
EMBO J.
16,
5687-5696
13.
Belaguli, N. S.,
Sepulveda, J. L.,
Nigam, V.,
Charron, F.,
Nemer, M.,
and Schwartz, R. J.
(2000)
Mol. Cell. Biol.
20,
7550-7558
14.
Moore, M. L.,
Wang, G. L.,
Belaguli, N. S.,
Schwartz, R. J.,
and McMillin, J. B.
(2001)
J. Biol. Chem.
276,
1026-1033
15.
Sepulveda, J. L.,
Belaguli, N.,
Nigam, V.,
Chen, C. Y.,
Nemer, M.,
and Schwartz, R. J.
(1998)
Mol. Cell. Biol.
18,
3405-3415
16.
Grepin, C.,
Nemer, G.,
and Nemer, M.
(1997)
Development
124,
2387-2395
17.
Morin, S.,
Charron, F.,
Robitaille, L.,
and Nemer, M.
(2000)
EMBO J.
19,
2046-2055
18.
Morimoto, T.,
Hasegawa, K.,
Kaburagi, S.,
Kakita, T.,
Masutani, H.,
Kitsis, R. N.,
Matsumori, A.,
and Sasayama, S.
(1999)
J. Biol. Chem.
274,
12811-12818
19.
Grepin, C.,
Dagnino, L.,
Robitaille, L.,
Haberstroh, L.,
Antakly, T.,
and Nemer, M.
(1994)
Mol. Cell. Biol.
14,
3115-3129
20.
Yao, T. P.,
Oh, S. P.,
Fuchs, M.,
Zhou, N. D.,
Ch'ng, L. E.,
Newsome, D.,
Bronson, R. T.,
Li, E.,
Livingston, D. M.,
and Eckner, R.
(1998)
Cell
93,
361-372
21.
Kirshenbaum, L. A.,
and Schneider, M. D.
(1995)
J. Biol. Chem.
270,
7791-7794
22.
Bishopric, N. H.,
Zeng, G. Q.,
Sato, B.,
and Webster, K. A.
(1997)
J. Biol. Chem.
272,
20584-20594
23.
Kakita, T.,
Hasegawa, K.,
Morimoto, T.,
Kaburagi, S.,
Wada, H.,
and Sasayama, S.
(1999)
J. Biol. Chem.
274,
34096-34102
24.
Grunstein, M.
(1997)
Nature
389,
349-352
25.
Mizzen, C. A.,
Yang, X. J.,
Kokubo, T.,
Brownell, J. E.,
Bannister, A. J.,
Owen-Hughes, T.,
Workman, J.,
Wang, L.,
Berger, S. L.,
Kouzarides, T.,
Nakatani, Y.,
and Allis, C. D.
(1996)
Cell
87,
1261-1270
26.
Struhl, K.
(1998)
Genes Dev.
12,
599-606
27.
Gu, W.,
and Roeder, R. G.
(1997)
Cell
90,
595-606
28.
Boyes, J.,
Byfield, P.,
Nakatani, Y.,
and Ogryzko, V.
(1998)
Nature
396,
594-598
29.
Soutoglou, E.,
Papafotiou, G.,
Katrakili, N.,
and Talianidis, I.
(2000)
J.
Biol. Chem.
275,
12515-12520
30.
Dallas, P. B.,
Yaciuk, P.,
and Moran, E.
(1997)
J. Virol.
71,
1726-1731
31.
Kwok, R. P.,
Lundblad, J. R.,
Chrivia, J. C.,
Richards, J. P.,
Bachinger, H. P.,
Brennan, R. G.,
Roberts, S. G.,
Green, M. R.,
and Goodman, R. H.
(1994)
Nature
370,
223-226
32.
Swope, D. L.,
Mueller, C. L.,
and Chrivia, J. C.
(1996)
J. Biol. Chem.
271,
28138-28145
33.
Molkentin, J. D.,
Kalvakolanu, D. V.,
and Markham, B. E.
(1994)
Mol. Cell. Biol.
14,
4947-4957
34.
Blobel, G. A.,
Nakajima, T.,
Eckner, R.,
Montminy, M.,
and Orkin, S. H.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
2061-2066
35.
Charron, F.,
Paradis, P.,
Bronchain, O.,
Nemer, G.,
and Nemer, M.
(1999)
Mol. Cell. Biol.
19,
4355-4365
36.
Stein, R. W.,
Corrigan, M.,
Yaciuk, P.,
Whelan, J.,
and Moran, E.
(1990)
J. Virol.
64,
4421-4427
37.
Chakravarti, D.,
Ogryzko, V.,
Kao, H. Y.,
Nash, A.,
Chen, H.,
Nakatani, Y.,
and Evans, R. M.
(1999)
Cell
96,
393-403
38.
Kundu, T. K.,
Palhan, V. B.,
Wang, Z.,
An, W.,
Cole, P. A.,
and Roeder, R. G.
(2000)
Mol. Cell
6,
551-561
39.
Korzus, E.,
Torchia, J.,
Rose, D. W.,
Xu, L.,
Kurokawa, R.,
McInerney, E. M.,
Mullen, T. M.,
Glass, C. K.,
and Rosenfeld, M. G.
(1998)
Science
279,
703-707
40.
Kraus, W. L.,
Manning, E. T.,
and Kadonaga, J. T.
(1999)
Mol. Cell. Biol.
19,
8123-8135
41.
Wada, H.,
Hasegawa, K.,
Morimoto, T.,
Kakita, T.,
Yanazume, T.,
and Sasayama, S.
(2000)
J. Biol. Chem.
275,
25330-25335
42.
Molkentin, J. D.
(2000)
J. Biol. Chem.
275,
38949-38952
43.
Yang, X. J.,
Ogryzko, V. V.,
Nishikawa, J.,
Howard, B. H.,
and Nakatani, Y.
(1996)
Nature
382,
319-324
44.
Eckner, R.,
Yao, T. P.,
Oldread, E.,
and Livingston, D. M.
(1996)
Genes Dev.
10,
2478-2490
45.
Yuan, W.,
Condorelli, G.,
Caruso, M.,
Felsani, A.,
and Giordano, A.
(1996)
J. Biol. Chem.
271,
9009-9013
46.
Nakajima, T.,
Uchida, C.,
Anderson, S. F.,
Lee, C. G.,
Hurwitz, J.,
Parvin, J. D.,
and Montminy, M.
(1997)
Cell
90,
1107-1112
47.
Nakajima, T.,
Fukamizu, A.,
Takahashi, J.,
Gage, F. H.,
Fisher, T.,
Blenis, J.,
and Montminy, M. R.
(1996)
Cell
86,
465-474
48.
Mink, S.,
Haenig, B.,
and Klempnauer, K. H.
(1997)
Mol. Cell. Biol.
17,
6609-6617
49.
Eckner, R.,
Arany, Z.,
Ewen, M.,
Sellers, W.,
and Livingston, D. M.
(1994)
Cold Spring Harbor Symp. Quant. Biol.
59,
85-95
50.
Svensson, E. C.,
Huggins, G. S.,
Dardik, F. B.,
Polk, C. E.,
and Leiden, J. M.
(2000)
J. Biol. Chem.
275,
20762-20769
51.
Fox, A. H.,
Kowalski, K.,
King, G. F.,
Mackay, J. P.,
and Crossley, M.
(1998)
J. Biol. Chem.
273,
33595-33603
52.
Orphanides, G.,
Lagrange, T.,
and Reinberg, D.
(1996)
Genes Dev.
10,
2657-2683
53.
Myer, V. E.,
and Young, R. A.
(1998)
J. Biol. Chem.
273,
27757-27760
54.
Oliner, J. D.,
Andresen, J. M.,
Hansen, S. K.,
Zhou, S.,
and Tjian, R.
(1996)
Genes Dev.
10,
2903-2911
55.
Morrisey, E. E.,
Ip, H. S.,
Tang, Z.,
and Parmacek, M. S.
(1997)
J. Biol. Chem.
272,
8515-8524
56.
Martinez-Balbas, M. A.,
Bannister, A. J.,
Martin, K.,
Haus-Seuffert, P.,
Meisterernst, M.,
and Kouzarides, T.
(1998)
EMBO J.
17,
2886-2893
57.
Zeng, X.,
Lee, H.,
Zhang, Q.,
and Lu, H.
(2001)
J. Biol. Chem.
276,
48-52
58.
Yamagata, T.,
Mitani, K.,
Oda, H.,
Suzuki, T.,
Honda, H.,
Asai, T.,
Maki, K.,
Nakamoto, T.,
and Hirai, H.
(2000)
EMBO J.
19,
4676-4687
59.
Slepak, T. I.,
Webster, K. A.,
Zang, J.,
Prentice, H.,
O'Dowd, A.,
Hicks, M. N.,
and Bishopric, N. H.
(2000)
J. Biol. Chem.
276,
7575-7585
60.
Guo, S.,
Cichy, S. B.,
He, X.,
Yang, Q.,
Ragland, M.,
Ghosh, A. K.,
Johnson, P. F.,
and Unterman, T. G.
(2001)
J. Biol. Chem.
276,
8516-8523
61.
Clerk, A.,
and Sugden, P. H.
(1999)
Am. J. Cardiol.
83,
64H-69H
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
H. Nishida, S. Miyagawa, M. Vieux-Rochas, M. Morini, Y. Ogino, K. Suzuki, N. Nakagata, H.-S. Choi, G. Levi, and G. Yamada Positive Regulation of Steroidogenic Acute Regulatory Protein Gene Expression through the Interaction between Dlx and GATA-4 for Testicular Steroidogenesis Endocrinology, May 1, 2008; 149(5): 2090 - 2097. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Takaya, T. Kawamura, T. Morimoto, K. Ono, T. Kita, A. Shimatsu, and K. Hasegawa Identification of p300-targeted Acetylated Residues in GATA4 during Hypertrophic Responses in Cardiac Myocytes J. Biol. Chem., April 11, 2008; 283(15): 9828 - 9835. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Viger, S. M. Guittot, M. Anttonen, D. B. Wilson, and M. Heikinheimo Role of the GATA Family of Transcription Factors in Endocrine Development, Function, and Disease Mol. Endocrinol., April 1, 2008; 22(4): 781 - 798. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kwintkiewicz, Z. Cai, and C. Stocco Follicle-Stimulating Hormone-Induced Activation of Gata4 Contributes in the Up-Regulation of Cyp19 Expression in Rat Granulosa Cells Mol. Endocrinol., April 1, 2007; 21(4): 933 - 947. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Karamboulas, A. Swedani, C. Ward, A. S. Al-Madhoun, S. Wilton, S. Boisvenue, A. G. Ridgeway, and I. S. Skerjanc HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage J. Cell Sci., October 15, 2006; 119(20): 4305 - 4314. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Xin, C. |